These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. Vichinsky E; Hoppe CC; Ataga KI; Ware RE; Nduba V; El-Beshlawy A; Hassab H; Achebe MM; Alkindi S; Brown RC; Diuguid DL; Telfer P; Tsitsikas DA; Elghandour A; Gordeuk VR; Kanter J; Abboud MR; Lehrer-Graiwer J; Tonda M; Intondi A; Tong B; Howard J; N Engl J Med; 2019 Aug; 381(6):509-519. PubMed ID: 31199090 [TBL] [Abstract][Full Text] [Related]
26. Increased hemoglobin affinity for oxygen with GBT1118 improves hypoxia tolerance in sickle cell mice. Dufu K; Williams AT; Muller CR; Walser CM; Lucas A; Eaker AM; Alt C; Cathers BE; Oksenberg D; Cabrales P Am J Physiol Heart Circ Physiol; 2021 Aug; 321(2):H400-H411. PubMed ID: 34213392 [TBL] [Abstract][Full Text] [Related]
27. The effect of the antisickling compound GBT1118 on the permeability of red blood cells from patients with sickle cell anemia. Al Balushi H; Dufu K; Rees DC; Brewin JN; Hannemann A; Oksenberg D; Lu DC; Gibson JS Physiol Rep; 2019 Mar; 7(6):e14027. PubMed ID: 30916477 [TBL] [Abstract][Full Text] [Related]
28. Targeting sickle cell disease root-cause pathophysiology with small molecules. Saunthararajah Y Haematologica; 2019 Sep; 104(9):1720-1730. PubMed ID: 31399526 [TBL] [Abstract][Full Text] [Related]
29. Voxelotor (GBT440) produces interference in measurements of hemoglobin S. Rutherford NJ; Thoren KL; Shajani-Yi Z; Colby JM Clin Chim Acta; 2018 Jul; 482():57-59. PubMed ID: 29601794 [No Abstract] [Full Text] [Related]
30. In vitro effects of NIPRISAN (Nix-0699): a naturally occurring, potent antisickling agent. Iyamu EW; Turner EA; Asakura T Br J Haematol; 2002 Jul; 118(1):337-43. PubMed ID: 12100171 [TBL] [Abstract][Full Text] [Related]
31. Identification of a small molecule that increases hemoglobin oxygen affinity and reduces SS erythrocyte sickling. Nakagawa A; Lui FE; Wassaf D; Yefidoff-Freedman R; Casalena D; Palmer MA; Meadows J; Mozzarelli A; Ronda L; Abdulmalik O; Bloch KD; Safo MK; Zapol WM ACS Chem Biol; 2014 Oct; 9(10):2318-25. PubMed ID: 25061917 [TBL] [Abstract][Full Text] [Related]
32. Nitric oxide reduces sickle hemoglobin polymerization: potential role of nitric oxide-induced charge alteration in depolymerization. Ikuta T; Thatte HS; Tang JX; Mukerji I; Knee K; Bridges KR; Wang S; Montero-Huerta P; Joshi RM; Head CA Arch Biochem Biophys; 2011 Jun; 510(1):53-61. PubMed ID: 21457702 [TBL] [Abstract][Full Text] [Related]
33. New antisickling agents. Labie D Haematologia (Budap); 1983; 16(1-4):105-8. PubMed ID: 6679483 [TBL] [Abstract][Full Text] [Related]
34. Voxelotor (GBT440), a first-in-class hemoglobin oxygen-affinity modulator, has promising and reassuring preclinical and clinical data. Estepp JH Am J Hematol; 2018 Mar; 93(3):326-329. PubMed ID: 29352729 [No Abstract] [Full Text] [Related]
36. Sickle hemoglobin oxygen affinity-shifting strategies have unequal cerebrovascular risks. Hebbel RP; Hedlund BE Am J Hematol; 2018 Mar; 93(3):321-325. PubMed ID: 29150874 [No Abstract] [Full Text] [Related]
37. Time resolved absorption study of the reaction of hydroxyurea with sickle cell hemoglobin. Kim-Shapiro DB; King SB; Bonifant CL; Kolibash CP; Ballas SK Biochim Biophys Acta; 1998 Mar; 1380(1):64-74. PubMed ID: 9545536 [TBL] [Abstract][Full Text] [Related]
38. Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocytes. Beddell CR; Goodford PJ; Kneen G; White RD; Wilkinson S; Wootton R Br J Pharmacol; 1984 Jun; 82(2):397-407. PubMed ID: 6733364 [TBL] [Abstract][Full Text] [Related]
39. Quantitative prediction of erythrocyte sickling for the development of advanced sickle cell therapies. Lu L; Li Z; Li H; Li X; Vekilov PG; Karniadakis GE Sci Adv; 2019 Aug; 5(8):eaax3905. PubMed ID: 31457104 [TBL] [Abstract][Full Text] [Related]
40. Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease. Han J; Saraf SL; Gordeuk VR Pharmacotherapy; 2020 Jun; 40(6):525-534. PubMed ID: 32343424 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]